Caravel Bio Wins $1.25M Grant to Expand Protein Engineering

The big picture: Caravel Bio, a biotechnology company developing AI-powered protein engineering technologies, has received a $1.25 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF). The funding will expand its platform for designing and manufacturing proteins with novel chemical properties. The company also appointed Michał Jastrzębski as Chief Technology Officer to lead its artificial intelligence initiatives.

Why it matters:

• Accelerated Discovery: The grant supports Caravel’s platform, which aims to overcome the bottleneck of expensive and time-consuming protein design testing, a critical challenge for AI-driven protein discovery.
• Expanded Capabilities: By enabling experimentation with non-canonical amino acids, Caravel’s technology could unlock new enzymes, therapeutic proteins, and biomaterials with properties currently difficult to achieve.
• Market Validation: The NSF grant, awarded to fewer than 5% of applicants, provides significant validation for Caravel’s approach and its potential commercial and societal impact in industrial biotechnology and beyond.

How it works:

• High-Throughput Experimentation: Caravel’s Artificial Evolution platform combines cell-free protein synthesis, microfluidic droplets, and bacterial spore display to test millions of protein designs simultaneously.
• Cost Reduction: The platform dramatically reduces the cost per experiment to a fraction of a cent, enabling extensive data generation for training advanced machine learning models.
• AI-Driven Iteration: Experimental data feeds directly into AI models, guiding subsequent rounds of protein design and testing to optimize for desired properties and manufacturing feasibility.

The catch: While Caravel’s approach to high-throughput experimentation is innovative, the broader field of AI-driven protein engineering is highly competitive, with numerous academic labs and well-funded startups pursuing similar goals. Translating laboratory improvements in enzyme stability or novel protein designs into scalable, commercially viable products remains a significant hurdle, requiring extensive validation and regulatory navigation beyond initial grant funding.

Key Facts

• Company: Caravel Bio
• Amount: $1.25M
• Round: Grant
• Investor: National Science Foundation (lead)
• Founders: Trevor Nicks, Ph.D., Emily Bowman, Ph.D.
• Sector: AI-powered Protein Engineering